DEA Raises 2027 Psychedelic Quotas, Previews Marijuana Plan

Photo by Michael via Pexels.

The DEA is proposing to make more of certain psychedelics next year, and in the same notice it is previewing how marijuana would be handled on a separate track. That is the headline version of the 2027 quota story, and it comes with a caveat worth stating early.

A Federal Register quota notice reads like accounting, but it is the clearest public signal of how much research supply federal regulators expect to need. The tables are dense and the figures in this piece are not verified, so check any gram figure against the Federal Register docket before relying on it.

What the 2027 Quota Notice Actually Says

The document at the center of this story is the proposed aggregate production quotas for Schedule I and II controlled substances for 2027. It is a proposal, not a final order. The Federal Register date, docket number and comment deadline are on the notice at federalregister.gov, and you should confirm them there before citing anything.

The headline reporting says certain psychedelics got higher quotas. Which ones, whether psilocybin, psilocin, MDMA, DMT or LSD, and by how many grams compared with 2026, is something to read directly from the notice's tables. This article does not state those figures because they have not been verified.

Timing follows a familiar pattern. Proposed quotas typically appear in the fall and carry a comment period of roughly 30 days. The DEA has also said plainly, in its 2026 final notice, that final quotas can differ from the proposed ones.

So treat every draft number as provisional. A proposed increase can shrink, grow or hold steady once comments are weighed, and nothing here is settled until the final order is published.

How Aggregate Production Quotas Work

Photo by KC_Woon via Pixabay.

Aggregate production quotas are the annual DEA limits on how much of each Schedule I and II substance can be manufactured in the United States. The agency sets them so that legitimate medical, scientific and industrial needs are met without leaving excess material in circulation.

The final 2026 order is the best baseline for comparison. It was published Monday, January 5, 2026 (Vol. 91, No. 2) under Docket No. DEA-1568E, and its Schedule I list includes dimethyltryptamine, or DMT, alongside amphetamine-type substances. Any 2027 figure should be read against that table.

The same notice also sets the assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine and phenylpropanolamine. Those are precursor chemicals, so they follow a related but distinct process.

In that 2026 notice, the DEA responded to comments about delays in getting medications. Its answer was that it monitors production proactively, which tells you the agency sees quotas as a living adjustment tool rather than a fixed ceiling.

One clarification matters for cannabis readers. A quota supports DEA-registered researchers and manufacturers. It has no bearing on state-level legality or on what a consumer can buy at a licensed shop.

Why Higher Psychedelic Quotas Matter for Research

For researchers, a quota is a practical bottleneck. Schedule I status means studies depend on DEA-registered suppliers, and those suppliers can only make what the aggregate quota allows. If the numbers are too tight, trials can stall waiting on material.

That is why a higher proposed quota is worth noticing. It suggests the agency expects more demand from registered researchers and manufacturers. It does not, by itself, mean new studies are approved or that any single trial will move faster.

Be careful about naming specific substances. Only the compounds confirmed in the notice itself should be described as seeing increases. And a larger quota is not an endorsement of any therapy. None of these substances is approved for treatment by virtue of a production number.

State programs live on a separate track. Some states run their own psilocybin programs under state rules, independent of the federal quota process. Those programs do not draw on the DEA's research allotment in any way a reader should assume.

Laws on psychedelics differ widely by state and country. Check your own jurisdiction's rules rather than inferring anything from a federal quota notice.

The Separate Marijuana Proposal and Rescheduling

The notice also previews a separate marijuana proposal. Details should be confirmed against the document itself. In past cycles, the DEA has proposed a distinct marijuana quota for registered researchers and manufacturers, and that is the likeliest frame for what is described here.

Marijuana is handled apart from the psychedelics because it sits in its own rescheduling process. Moving it from Schedule I to Schedule III is a separate regulatory question, and the quota machinery simply has to account for whatever schedule it occupies.

The current rescheduling status as of mid-November 2026 is not verified for this piece. Three things need checking: whether a final rule moving marijuana to Schedule III has been issued, whether an administrative law judge hearing took place, and whether any court challenge or executive action is pending. Marijuana Moment and the DEA press office track these closely.

A production quota is not a rescheduling decision. It does not change state-licensed markets, and it does not by itself alter 280E tax treatment, which is the issue dispensary operators care most about.

My read: the quota proposal is a technical signal, and the rescheduling status is what actually moves the industry. If you run a licensed business, watch the rescheduling docket first and the quota tables second.

What to Watch Before the Quotas Are Finalized

Start with the primary sources. The comment docket on regulations.gov holds the notice and public comments, and the DEA Diversion Control Division site at deadiversion.usdoj.gov carries quota notices with exact figures and deadlines.

Several things can still change before the order is final:

• The final quota numbers for each psychedelic, up or down from the proposal.
• Any revised language on the separate marijuana proposal.
• The timeline for the final order. The 2026 cycle showed it arriving around the start of the year, with that order published January 5.

Because the specifics are still moving, read the Federal Register entry itself and current rescheduling news rather than relying on summaries, including this one. Secondhand figures on quota stories get garbled quickly.

Finally, cannabis and psychedelic laws vary by state and country. Confirm your local rules before acting on anything you read about federal policy.

The most useful way to read this story is as a supply signal. The DEA is planning for more psychedelic research material, and the final order will show whether that plan holds once comments are in.

Marijuana's path runs through rescheduling, not quotas, so the next real change will come from that process. When the final 2027 order is published, it is the document to read, tables and all.

Browse our seed collection.